Giovanni Viegi Primo Ricercatore CNR Responsabile Unità di Epidemiologia Ambientale Polmonare,

1. Workshop “Definizione dell’immagine di salute di un’area urbana per l’aiuto alle decisioni: Casi di studio di Pisa ed esperienze toscane Pisa, Area Ricerca CNR, 16 maggio 2005 Opportunità nel 7° Programma Quadro della Ricerca (2007-2013) dell’Unione Europea Giovanni Viegi Primo Ricercatore CNR Responsabile Unità di Epidemiologia Ambientale Polmonare, Istituto di Fisiologia Clinica CNR, Pisa Professore di “Effetti dell’inquinamento sulla salute”, Corso di Laurea in Scienze Ambientali, Università di Pisa 2004-05 President Elect, European Respiratory Society (ERS)

2. Workshop “Definizione dell’immagine di salute di un’area urbana per l’aiuto alle decisioni: Casi di studio di Pisa ed esperienze toscane Pisa, Area Ricerca CNR, 16 maggio 2005 Opportunità nel 7° Programma Quadro della Ricerca (2007-2013) dell’Unione Europea Giovanni Viegi Primo Ricercatore CNR Responsabile Unità di Epidemiologia Ambientale Polmonare, Istituto di Fisiologia Clinica CNR, Pisa Professore di “Effetti dell’inquinamento sulla salute”, Corso di Laurea in Scienze Ambientali, Università di Pisa 2004-05 President Elect, European Respiratory Society (ERS)

3. Science and Research in the European Union EU and research policies – Opportunities in the 7th EU Research Framework Programme (2007-2013) Giovanni Viegi, MD . National Research Council (CNR) Director of Research, Head, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy . Professor of “Effects of pollution on health”, Faculty of Environmental Sciences, University of Pisa 2005-06 President, European Respiratory Society (ERS)

9. I - COOPERATION PROGRAMME (€44.7 billion) • The COOPERATION Programme, as indicated above, will provide support to trans-national cooperation at every scale across the European Union and beyond in a number of thematic areas corresponding to major fields where research must be supported and strengthened to address European social, economic and industrial challenges. Nine themes (see above) have been determined for EU action.

10. For each of these themes, a series of activities have been identified which indicate the broad lines envisaged for EU support. Under each theme, besides the topics above, it will be possible to address in an open and flexible way, two types of needs: emergingneeds (specific support to spontaneous research proposals to further new scientific and technological opportunities); unforeseen policy needs to respond, in a flexible way, to new policy needs that arise during the course of the FP, related to unforeseen developments or events requiring a quick reaction (e.g. SARS epidemic or BSE crisis).

11. Across all these thematic areas, EU support to European collaboration will be implemented through four types of tools and categories of activities: • Collaborative research: Core activity with the objective to establish excellence research projects and networks able to attract researchers and investments. • Joint Technology Initiatives: To set up, under very specific conditions, long term public-private partnerships that will combine private sector investment with and national and European public funding. • Co-ordination of national research programmes: To strengthen the tools used so far for the coordination of national and regional research activities. • International Co-operation: Opening of the activities of the 7th framework to third countries to increase their participation and the creation of specific co-operation actions

13. 1.1 Biotechnology, generic tools and technologies for human health (A) • High-throughput research. To catalyse experimental progress in biomedical research by enhancing data generation, standardisation, acquisition and analysis. • Detection, diagnosis and monitoring, with emphasis on non-invasive or minimally invasive approaches. • Predicting suitability, safety and efficacy of therapies. To develop and validate biological markers, methods and models, including simulation, pharmaco-genomics, targeting approaches and alternatives to animal testing. • Innovative therapeutic approaches and intervention. To consolidate and ensure further developments in advanced therapies and technologies with potential application in many diseases and disorders.

14. 1.2- Translating research for human health (B) • Integrating biological data and processes: Large scale data gathering. Systems biology. To generate and analyse the vast amount of data needed to understand better the complex regulatory network of thousands of genes and gene products controlling important biological processes. • Research on the brain and related diseases, human development and ageing. To explore the process of healthy ageing and the way brain interacts with genes and environment as well as brain diseases. • Translational research in infectious diseases. To address anti-microbial drug resistance, the global threats of HIV/AIDS, malaria and tuberculosis as well as emerging epidemics (e.g. SARS and highly pathogenic influenza). • Translational research in major diseases:cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases (e.g. osteoarthritis). To develop patient-oriented strategies from prevention to diagnosis and treatment, including clinical research.

15. 1.3- Optimising the delivery of health care to European citizens (C) • Translating clinical outcome into clinical practice. To understand clinical decision-making and how to translate outcomes of clinical research into clinical practice, and specially addressing the specificities of children women and elderly population. • Quality, efficiency and solidarity of health systems including transitional health systems. To translate effective interventions into management decisions, to ensure an adequate supply of human resources, to analyse factors influencing equity of access to health care. • Enhanced disease prevention and better use of medicines. To develop efficient public health interventions addressing wider determinants of health (such as stress, diet or environmental factors). To identify successful interventions in different health care settings for improving the prescription of medicines and improving their use by patients (including pharmaco-vigilance). • Appropriate use of new health therapies and technologies. Long term safety aspects and monitoring of large scale use of new medical technologies (including devices) and advanced therapies ensuring a high level of protection for human health.

16. 2- FOOD, AGRICULTURE AND BIOTECHNOLOGY (€2.47 billion) • This theme intends to build a European Knowledge Based Bio-Economy by bringing together science, industry and other stakeholders, in order to exploit emerging research opportunities with the view of addressing new social and economic challenges (demand for healthier food, increasing risks of epizootic and zoonotic diseases, food related disorders…) • (Activities Relevant to ERS): • “Fork to farm”: Food health and well being: Consumer, societal and health aspects of food and feed, including behavioural and cognitive sciences; nutrition and diet related diseases including obesity.

17. 3- Information and communication technologies (€12.76 billion) • The objective of this theme is to enable Europe to master and shape the future developments in Information and Communication Technologies (ICT) so the demands of its society and economy are met. Community support will strengthen Europe’s scientific and technology base in ICT. (Activities relevant to ERS): 3.1- Application Research • ICT meeting societal challenges. New systems and services in areas of public interest, improving quality efficiency, accesses and inclusiveness. • For Health: improving disease prevention, early diagnosis and personalisation; autonomy, safety and mobility of patients through personal health monitoring systems; health information space for knowledge discovery.

18. 4-Nanosciences, nanotechnologies, materials and new production technologies (€4.86 billion) • The objective is to improve competitiveness of European industry and ensure its transformation from a resource-intensive to a knowledge-intensive industry, by generating breakthrough knowledge for new applications. (Themes and activities relevant to ERS) 4.1-Nanosciences, nanotechnologies • Impact of nano-escale entities on human safety, health and the environment;

19. (Not relevant to ERS activities) • 5- Energy • 8- Socio-Economic Sciences and the Humanities • 9- Space and security research

22. part I of II

23. II - IDEAS PROGRAMME (€12 billion) • The objective of this new action is to enhance the dynamism, creativity and excellence of European Research at the frontier of knowledge. This will be done by supporting “investigator-driven” research projects carried out across all fields by individual teams in competition at European scale. Projects will be funded on the basis of proposals presented by the researchers on subjects of their choice, and evaluated on the sole criterion of excellence as judged by peer review. Activities • This action will respond to the most promising and productive areas of research and the best opportunities for scientific and technological progress, within and across disciplines, including engineering and social sciences and the humanities. It will be implemented independently of the thematic orientations of the other parts of the framework programme and will pay attention to young researchers and new groups as well as established groups.

24. III - PEOPLE PROGRAMME(€7.2 billion) • The objective will be to strengthening, quantitatively and qualitatively, the human potential in research and technology in Europe, by stimulating people to enter into the researcher’s profession, encouraging European researchers to stay in Europe and attracting to Europe researchers from the entire world. This will be done by putting into place a coherent set of “Marie Curie” Actions, addressing researchers at all stages of their careers, from the initial research training to their life long learning and career development. Activities • Initial training of researchers • Life-long training and career development • Industry-academia pathways and partnership • The international dimension • Specific actions

25. IV – CAPACITES PROGRAMME (€7.5 billion) • This part of the Framework programme will enhance research and innovation capacities throughout Europe and ensure their optimal use. This aim will be achieved through: Activities • Optimising the use and development of research infrastructures (Research infrastructures) • Strengthening innovative capacities of SME’s and their ability to benefit from research (Research for the benefits of SME’s) • Supporting the development of regional research-driven clusters (Regions of knowledge) • Unlocking the research potential in the EU’s convergence and outermost regions (Research potential) • Bringing science and society closer together for the harmonious integration of science and technology in the European society (Science and society) • Horizontal actions and measures in support of international co-operation (Activities of international co-operation)

26. part II of II

27. EU Projects - ERS • CA-COPD (BIOMED I) • AFORDEE (5° FP) • THADE (DG-SANCO) • HESE (DG-SANCO) • EnVIE (6° FP) • IMCA (DG-SANCO)

28. AFORDEE (5° FP)